2003•Zenodo (CERN European Organization for Nuclear Research)Open access
Advances in the chemistry of thiazolidinediones as antidiabetic agents
Narendra Nath Ghosh, Dipti Gupta, Jyoti Chaudhary, Sulekh Chand, Sujata K. Dass, Chandra, Ramesh
Open full text 4 citations
Abstract
Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi-110 007, India E-mail : acbrdu@hotmail.com Fax : 91-11-27666248 Dr. Zakir Hussain College, University of Delhi, Delhi-110 002, India Department of Medicine, V. P. Chest Institute, University of Delhi, Delhi-10 007, India Manuscript received 5 September 2003 Several thiazolidinedione classes of compounds (drugs) found to he very effective in reducing insulin resistance or to efficiently potentiate insulin action in type 2 non insulin-dependent diabetes mellitus (NIDDM) patients; the structure-activity relationship of such related compounds, similar to ciglitazone, giving rise to the development of troglitazone, englitazone, pioglitazone and rosiglitazone as new drug entities for diabetes, and several studies showing that analogs of these classes interact with a nuclear receptor PPARϒ and transcript the insulin sensitizing genes form the subject-matter of this review.